Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $133,870.38 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 5,887 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $22.74, for a total value of $133,870.38. Following the transaction, the insider directly owned 215,747 shares in the company, valued at $4,906,086.78. This represents a 2.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Down 3.4%

Shares of KMTS opened at $25.06 on Thursday. Kestra Medical Technologies, Ltd. has a fifty-two week low of $14.10 and a fifty-two week high of $30.00. The business has a 50-day moving average of $22.78 and a 200 day moving average of $22.52. The firm has a market cap of $1.47 billion, a P/E ratio of -10.36 and a beta of 0.58. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research raised their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research report on Wednesday, July 15th. The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and an average price target of $27.83.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new position in shares of Kestra Medical Technologies in the first quarter worth $11,036,000. Woodline Partners LP bought a new stake in Kestra Medical Technologies during the first quarter valued at $2,510,000. Jane Street Group LLC purchased a new position in Kestra Medical Technologies during the first quarter worth about $756,000. Geode Capital Management LLC increased its stake in Kestra Medical Technologies by 718.5% in the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock worth $5,395,000 after acquiring an additional 285,579 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Kestra Medical Technologies in the 2nd quarter valued at about $256,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.